World’s First CRISPR-Based Gene Therapy Authorized by UK’s MHRA

A groundbreaking treatment for sickle-cell disease and transfusion-dependent β-thalassemia using the biomedical advancement of CRISPR technology has been authorized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for patients aged 12 and over.
Source: Drug Industry Daily